Trial record 1 of 1 for:    NCT00583544
Previous Study | Return to List | Next Study

A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers (SRD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00583544
Recruitment Status : Completed
First Posted : December 31, 2007
Last Update Posted : July 18, 2008
Information provided by:
Targacept Inc.

December 20, 2007
December 31, 2007
July 18, 2008
January 2007
January 2008   (Final data collection date for primary outcome measure)
hematology, biochemistry, urine analysis, vital sign, ECG, adverse events. [ Time Frame: 4 days ]
Same as current
Complete list of historical versions of study NCT00583544 on Archive Site
plasma and urine pharmacokinetics, Pharmaco EEG, Bond-Lader Visual Analogue Scal [ Time Frame: 4 days ]
Same as current
Not Provided
Not Provided
A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers
A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.
Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Drug: TC-2216
Multiple ascending dose groups will be explored.
  • Placebo Comparator: 1
    Intervention: Drug: TC-2216
  • Experimental: 2
    Intervention: Drug: TC-2216
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
February 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male subjects aged 18-40 years old (both ages included).
  2. Subjects must be in good health as determined by their medical history, physical examination, psychological examination, ECG, vital signs, standard EEG and laboratory tests. A volunteer with a clinical abnormality may be included only if the Investigator or his designee considers that the abnormality will not introduce additional risk factor for the subject's health, or interfere with the study objectives.
  3. Subjects with a body mass index within the range 18-29 kg/m2 and a weight within the range of 60-90 kg.
  4. Non-smoker subjects (a cotinine test will be performed at screening and Day -1
  5. Subjects must be able to refrain from consuming xanthine containing beverages, and must refrain from intensive physical exercise during the study conduct (until the end of study visit).
  6. Subjects must have signed an informed consent form indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions.
  7. Subjects must be affiliated with, or a beneficiary of, a French social security system.

Exclusion Criteria:

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Any clinically relevant acute or chronic diseases which could interfere with the subjects safety during the trial, or expose them to undue risk, or which could interfere with the study objectives.
  2. History or presence of gastrointestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  3. Any history of drug or other significant allergy.
  4. Likely to need any treatment (including dental care) during the study period.
  5. Donation of one or more units of blood within 90 days prior to the screening.
  6. Use of any prescription or over-the-counter medication within 14 days prior to admission on Day-1 (not including paracetamol in the range of 1gr/day). In addition any medications with central effects are prohibited for a period equal to 5 x half-life prior to admission (Day-1), should this period be longer than 14 days.
  7. Alcohol consumption > 40 g alcohol/day (1 glass (25 cl) of beer with 3° of alcohol = 7.5 g, or 1 glass (25 cl) of beer with 6° of alcohol = 15 g, or 1 glass (12.5 cl) of wine with 10° of alcohol = 12 g, or 1 glass (4cl) of aperitif with 42° of alcohol = 17 g).
  8. Positive alcotest at screening and Day -1 .
  9. Positive test result on hepatitis B surface antigen, hepatitis C antibody.
  10. Positive test result on HIV 1 and 2 serology.
  11. Excessive daily consumption of xanthines containing drinks (i.e > 500 mg/day of caffeine).
Sexes Eligible for Study: Male
18 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Geoffrey Dunbar, Vice President, CDRA, Targacept, Inc
Targacept Inc.
Not Provided
Study Director: Targacept Clinical Trials, MD Targacept Inc.
Targacept Inc.
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP